Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Argus Health
McKinsey
Farmers Insurance
Harvard Business School
Teva
AstraZeneca
Moodys
Covington
Deloitte

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: RE44847

« Back to Dashboard

Which drugs does patent RE44847 protect, and when does it expire?

Patent RE44847 protects OTREXUP and is included in one NDA.

This patent has thirteen patent family members in eight countries.
Summary for Patent: RE44847
Title:Needle assisted jet injector
Abstract: A needle assisted jet injector and method for jet injecting medicament are disclosed. In one embodiment of the injector, the needle is retractably located within an injector nozzle assembly. Upon activation of the force generating source, a portion of the needle extends past the nozzle assembly and penetrates the outer layer of skin to deliver the medicament via jet injection to a deeper region. After activation, the needle retracts back into the nozzle assembly. In another embodiment, the needle is fixed to the end of the nozzle assembly. In both embodiments, the length of the portion of the needle that penetrates the skin is less than 5 mm.
Inventor(s): Sadowski; Peter L. (Woodbury, MN), Deboer; David M. (Grand Rapids, MI), Berman; Claude L. (Effingham, NH), Lesch, Jr.; Paul R. (Lino Lakes, MN), Holland; Margaret L. (New Haven, CT)
Assignee: Antares Pharma, Inc. (Ewing, NJ)
Application Number:13/530,974
Patent Claim Types:
see list of patent claims
Use; Device; Delivery; Dosage form;

Drugs Protected by US Patent RE44847

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN No No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-007 Mar 24, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-008 Mar 24, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-004 Oct 11, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent RE44847

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,776,015 Needle assisted jet injector ➤ Subscribe
6,428,528 Needle assisted jet injector ➤ Subscribe
6,565,553 Needle assisted jet injector ➤ Subscribe
RE44846 Needle assisted jet injector ➤ Subscribe
7,744,582 Needle assisted jet injector ➤ Subscribe
6,746,429 Needle assisted jet injector ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE44847

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2002522171 ➤ Subscribe
European Patent Office 1336419 ➤ Subscribe
Spain 2229183 ➤ Subscribe
Japan 4299466 ➤ Subscribe
Australia 5470499 ➤ Subscribe
China 1323230 ➤ Subscribe
China 1212867 ➤ Subscribe
Germany 69908140 ➤ Subscribe
Germany 69921704 ➤ Subscribe
European Patent Office 1104317 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
Colorcon
Moodys
Deloitte
Daiichi Sankyo
Julphar
Cipla
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot